Is CytomX Therapeutics, Inc. (CTMX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 12.7% / 30% | 0.4% / 30% | 5.17% / 5% | ✗ NOT HALAL |
| DJIM | 1.2% / 33% | 12.7% / 33% | 0.4% / 33% | 5.17% / 5% | ✗ NOT HALAL |
| MSCI | 7.8% / 33% | 83.5% / 33% | 2.6% / 33% | 5.17% / 5% | ✗ NOT HALAL |
| S&P | 1.2% / 33% | 12.7% / 33% | 0.4% / 33% | 5.17% / 5% | ✗ NOT HALAL |
| FTSE | 7.8% / 33% | 83.5% / 33% | 2.6% / 50% | 5.17% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -3790.6% | |
| Net Margin | -22.8% | |
| Return on Equity (ROE) | -35.2% | |
| Return on Assets (ROA) | -9.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$76M |
| Free Cash Flow | -$76M |
| Total Debt | $4M |
| Debt-to-Equity | 4.3 |
| Current Ratio | 3.1 |
| Total Assets | $152M |
Price & Trading
| Last Close | $4.42 |
| 50-Day MA | $5.25 |
| 200-Day MA | $3.59 |
| Avg Volume | 6.2M |
| Beta | 2.5 |
|
52-Week Range
$0.40
| |
About CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CytomX Therapeutics, Inc. (CTMX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CytomX Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CytomX Therapeutics, Inc.'s debt ratio?
CytomX Therapeutics, Inc.'s debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.8%.
What are CytomX Therapeutics, Inc.'s key financial metrics?
CytomX Therapeutics, Inc. has a market capitalization of $977M, and revenue of $76M. The company maintains a gross margin of 100.0% and a net margin of -22.8%. Return on equity stands at -35.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.